Monoclonal Antibody Use in Post-Acute and Long-Term Care: A Call to Action

Older adults, specifically those residing in nursing homes, recently experienced the most significant increase in COVID-19 cases and death in the United States.1 Monoclonal antibody (mAb) treatments are the only currently available outpatient antiviral treatment available for COVID-19.2 MAb awareness, access, and administration remain significant challenges in post-acute and long-term care (PALTC) facilities. We provide tools and strategies to address these challenges.